| Date | Title | Description |
| 22.04.2025 | Trump looking at cutting US drug prices to international levels, sources say | Trump looking at cutting US drug prices to international levels, sources say
By Patrick WingroveApril 22, 20251:59 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Item 1 of 2 Illustration photo ... |
| 22.04.2025 | Stocks making the biggest moves after hours: Tesla, Enphase Energy, Oklo, Bristol Myers Squibb and more | - |
| 15.04.2025 | Назад, в генетическое будущее | - |
| 09.04.2025 | Pharmaceutical stocks rise as Trump pauses tariffs but not for China | Some pharmaceutical stocks rose after President Donald Trump said he would pause most so-called reciprocal tariffs, temporarily easing fears about the impact of potential tariffs on pharmaceuticals .
Shares of most U.S.-based companies turn... |
| 03.04.2025 |
Jim Cramer says investors should follow the post-dot-com-bubble playbook | Monday - Friday, 6:00 - 7:00 PM ET
As stocks cratered Thursday following Trump’s tariff announcements, CNBC’s Jim Cramer recommended investors follow the playbook used after the dot-com bubble burst.
Cramer highlighted sectors like health c... |
| 02.04.2025 | Latest Innovation in Automation and AI/ML Presented at the 11th Annual Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Top biopharmas and leading biotechs discuss new trends in AI/ML and share how th... |
| 01.04.2025 | Trump’s tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks | - |
| 31.03.2025 | Don’t overlook the impact of pharma tariffs, says an analyst. Where we stand on Bristol Myers | - |
| 28.03.2025 | These dividend stocks will benefit from longevity’s ‘transformational’ opportunity, UBS says | - |
| 26.03.2025 | CHOSA to Unveil Predictive Data for Cisplatin Response in Lung Cancer at end Q2 2025 – Advancing Precision Medicine for the World’s Most Widely Used Cancer Drug | CHOSA to Unveil Predictive Data for Cisplatin Response in Lung Cancer at end Q2 2025 – Advancing Precision Medicine for the World’s Most Widely Used Cancer Drug
Wed, Mar 26, 2025 14:11 CET Report this content
The English text is an unoffici... |
| 22.03.2025 | America needs a jab in its corporate backside | - |
| 21.03.2025 | The Biotech Boom and the Opioid Reckoning: A Tale of Two Industries | In the heart of Europe, a new wave of biotech innovation is rising. Sofinnova Partners has closed a €165 million fund, the Sofinnova Biovelocita II. This fund is a beacon for startups, illuminating the path for groundbreaking therapies. It’... |
| 21.03.2025 | NVIDIA GTC: AI Innovation Driving Change in Healthcare and Drug Discovery | - |
| 20.03.2025 | The aging population is a $1 trillion opportunity. These stocks are the winners, says Mizuho | - |
| 19.03.2025 | Sofinnova Partners: €165M Biotech Acceleration Fund Closed | Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the final close of Sofinnova Biovelocita II. This fund has exceeded its target, successfully raising €165 million, with s... |
| 19.03.2025 | Beijing woos global executives as FDI slides, trade tensions build | Beijing woos global executives as FDI slides, trade tensions build
By Xiuhao Chen and Ryan WooMarch 19, 20259:51 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
China's and U.S.' flags are seen ... |
| 18.03.2025 | Qualified Digital Announces Acquisition of Xpediant Digital | Qualified Digital (QD), a leading full-service digital business and experience agency, has announced its acquisition of Xpediant Digital, a premier provider of content supply chain automations for Pharma and Life Sciences as a services and ... |
| 14.03.2025 | JPMorgan says own this drug stock. It’s one Jim Cramer is itching to buy again | JPMorgan touts Bristol Myers Squibb as a top biopharma pick. Jim Cramer is also quite fond of it. |
| 12.03.2025 | Выпускайте субстанцию: фарма ищет лучшую версию себя | - |
| 11.03.2025 | Navigating Market Currents: A Strategic Shift in Investments | In the ever-changing landscape of the stock market, strategic decisions can feel like navigating a ship through turbulent waters. Investors must adjust their sails to catch the right winds. Recently, two notable trades have emerged, showcas... |
| 11.03.2025 | Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 11, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeut... |
| 07.03.2025 | We’re trimming a winner in the market rotation and using the cash to buy more of a laggard | We are making two trades Friday:
Selling 100 shares of Bristol Myers Squibb at roughly $62.39. Following the trade, Jim Cramer’s Charitable Trust will own 1,700 shares of BMY, decreasing its weighting to about 3.10% from 3.3%.
Buying 15 sha... |
| 24.02.2025 | Market comeback loses steam, but here’s why Bristol Myers is still having a strong day | Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. |
| 20.02.2025 | BioArctic's Bold Moves in Alzheimer's Treatment: A New Era of Hope | In the world of biopharmaceuticals, the race against neurodegenerative diseases is relentless. BioArctic AB, a Swedish company, is at the forefront of this battle, armed with innovative technologies and strategic partnerships. Recent develo... |
| 20.02.2025 | JPMorgan’s top biopharma picks for 2025 | - |
| 20.02.2025 | BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing | BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
Thu, Feb 20, 2025 06:30 CET Report this content
Stockholm, Sweden, February 20, 2... |
| 19.02.2025 | Ambrosia Biosciences Further Strengthens Board of Directors with Appointment of Jason Haddock | logo
Mr. Haddock brings more than 25 years of financial and operational experience as Ambrosia advances preclinical pipeline
BOULDER, Colo., Feb. 19, 2025 /PRNewswire-PRWeb/ -- Ambrosia Biosciences Inc. ("Ambrosia"), today announc... |
| 17.02.2025 | The Future of Pharmaceuticals: Innovations and Challenges in 2025 | The pharmaceutical landscape is shifting. New technologies and innovative treatments are emerging, promising to change the way we approach healthcare. In 2025, two companies stand at the forefront: BioArctic and TAHO Pharmaceuticals. Each i... |
| 17.02.2025 | TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant | TAIPEI, Feb. 17, 2025 /PRNewswire/ -- TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first Apixaban oral dissolving film (ODF). The study confirmed that TAH3311 is bioequivalent to... |
| 13.02.2025 | FreeOx Biotech Celebrates Landmark 2024 with Record Growth: New Hires, Groundbreaking Trial Selections, and Major Funding Milestones | FreeOx Biotech
Innovative Biotech Company Expands Executive Team with Three C-Suite Appointments and Advances Pipeline with Key Trial Evaluations
BARCELONA and PALO ALTO, Feb. 13, 2025 /PRNewswire-PRWeb/ -- FreeOx Biotech, a clinical-stage ... |
| 13.02.2025 | Interim Report for the period October – December 2024 | Interim Report for the period October – December 2024
Thu, Feb 13, 2025 08:00 CET Report this content
Pioneering license agreement with BrainTransporter™ signed with BMS worth up to USD 1.35 billion plus royalties
Events during the fourth q... |
| 11.02.2025 | UltraSight™ to Expand Access to Echocardiographic Monitoring for Obstructive Hypertrophic Cardiomyopathy Patients | In a new study, non-sonographers to use UltraSight™ Real-Time Guidance for patients that require echocardiogram
By applying the power of machine learning to imaging, our aim is to streamline patient cardiac workflows with UltraSight™ Real-T... |
| 07.02.2025 | Weak Guidance from Bristol-Myers Could Be Creating an Opportunity Bristol-Myers stock fell after earnings, but analysts remain bullish which suggests that any dip in the stock may create a buying oppo... |
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the... |
| 27.01.2025 | The 2025 PDA Board of Directors: A Diverse Range of Interests and Expertise | The 2025 PDA Board of Directors
The officers and directors represent pharmaceutical/biopharmaceutical businesses of all sizes and areas of competency across the United States, Europe and Asia.
BETHESDA, Md., Jan. 27, 2025 /PRNewswire-PRWeb/... |
| 21.01.2025 | TAHO Pharmaceuticals Completes Pivotal Trial of TAH3311, the First Oral Dissolving Film Anticoagulant | TAIPEI, Jan. 21, 2025 /PRNewswire/ -- TAHO Pharmaceuticals is pleased to announce the successful completion of the pivotal trial for TAH3311, the first anticoagulant oral dissolving film (ODF). This trial was conducted following detailed di... |
| 18.01.2025 | Medicare's Drug Price Negotiations: A New Era for Prescription Costs | In a significant shift, Medicare is stepping into the ring to negotiate drug prices. This change aims to alleviate the financial burden on millions of seniors. The latest announcement includes 15 new drugs, bringing the total to 25. These d... |
| 17.01.2025 | Ozempic, Wegovy and other drugs are among 15 selected for Medicare’s price negotiations | That brings the total to 25 drugs that will have lower price tags for Medicare enrollees.
Together, those 25 drugs account for a third of Medicare spending on prescriptions, Becerra said. Ozempic and Wegovy, in particular, have been scrutin... |
| 17.01.2025 | LOTTE BIOLOGICS to Present at the 2025 J.P. Morgan Healthcare Conference | New CEO James Park Delivers First Presentation at J.P. Morgan Healthcare Conference on "Advancing as a Global CDMO Leader"
Unveiling of Next-Generation ADC Platform 'SoluFlex Link': Enabling High-Potency, High-Yield ADC Developmen... |
| 16.01.2025 | BioWorld by Clarivate Releases Comprehensive 2024 Year in Review | Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year
LONDON, Jan. 16, 2025 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, ha... |
| 16.01.2025 | Light Horse: $62 Million (Series A) Raised For Developing Small Molecule Therapeutics | Light Horse Therapeutics – a first-in-class small molecule therapeutics developer – announced a $62 million Series A funding round. This funding was led by founding investor Versant Ventures and included Mubadala Capital and three strategic... |
| 15.01.2025 | Be Bio Closes $92M Series C Financing | Be Bio, a Cambridge, MA-based company which specializes in B Cell Medicines (BCMs), raised $92M in Series C funding.
The round was led by Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management,... |
| 14.01.2025 | Overhaul's $55 Million Boost: A Game Changer in Supply Chain Management | In the fast-paced world of logistics, clarity is gold. Overhaul, a Texas-based company, just struck it rich with a $55 million funding round. This infusion of capital is more than just numbers; it’s a lifeline for innovation. The investment... |
| 13.01.2025 | Overhaul Raises $55M in Funding | Overhaul, an Austin, TX-based supply chain risk management and intelligence company, raised $55M in equity funding.
The round was led by Springcoast Partners with participation from existing investors Edison Partners and Americo. As part of... |
| 13.01.2025 | Kardigan: $300 Million Raised For Modernizing Cardiovascular Drug Development | Kardigan – a heart health company modernizing cardiovascular drug development – announced it launched with a mission to develop multiple targeted treatments in parallel, bringing people with cardiovascular diseases closer to the cures they ... |
| 10.01.2025 | Light Horse Therapeutics Raises $62M in Series A Financing | Light Horse Therapeutics, a San Diego, CA-based developer of small molecule therapeutics, raised $62M in Series A funding.
The round was led by Versant Ventures and included Mubadala Capital as well as Bristol-Myers Squibb Co, Taiho Venture... |
| 10.01.2025 | JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma | SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Dr... |
| 08.01.2025 | Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report | Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care
LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today ... |
| 07.01.2025 | GORTEC Announces New Trial Success for Head and Neck Cancer Treatment | TOURS, France, Jan. 7, 2025 /PRNewswire/ -- GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy,... |
| 06.01.2025 | General Proximity Raises $16M in Funding | General Proximity, a San Francisco, CA-based biotech platform company, raised $16M in funding.
The round was led by Aydin Senkut at Felicis. Other investors included Y Combinator, age1, Modi Ventures, Wilson Sonsini, as well as a number of ... |
| 31.12.2024 | Drugmakers to raise US prices on over 250 medicines starting Jan. 1 | Drugmakers to raise US prices on over 250 medicines starting Jan. 1
By Michael ErmanDecember 31, 20246:02 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
U.S. dollar banknotes and medicines are ... |
| 27.12.2024 | FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo | FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
By Sneha S K and Sriparna RoyDecember 27, 20245:16 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Bottles and a IV b... |
| 19.12.2024 | Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare | SHANGHAI, Dec. 19, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a pioneer in Internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb ("BMS") China... |
| 19.12.2024 | BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program | BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program
Thu, Dec 19, 2024 07:30 CET Report this content
Stockholm, Sweden, December 19, 2024 – BioArctic AB (publ) (N... |
| 13.12.2024 | Procurement in 2025: From ‘should we try AI?’ to ‘When can we start?’ | A July 2024 Gartner survey found that 72% of procurement leaders are prioritising the integration of GenAI into their strategies. Gartner predicts that as AI agents become more embedded in procurement technology, they will transform the rol... |
| 13.12.2024 | Tasca Therapeutics: Drug Discovery Platform Secures $52 Million (Series A) | Tasca Therapeutics, a biotechnology company that utilizes a unique drug discovery platform that identifies and maps novel lipid-binding pockets on proteins to develop new medicines to treat human diseases, announced a $52 million Series A f... |
| 08.12.2024 | Nuvig: $161 Million (Series B) Raised To Develop Novel Immunomodulatory Therapeutics | Nuvig Therapeutics – a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases – announced the closing of a $161 million Series B round. The funding was co-led b... |
| 05.12.2024 | Nuvig Therapeutics Raises $161M in Series B Funding | Nuvig Therapeutics, a Menlo Park, CA-based privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, raised $161M in Series B funding.
The round was led by Sanofi... |
| 04.12.2024 | Hedge Funds and Healthcare: A New Frontier in Investment Strategy | In the world of finance, the dance between risk and reward is a constant. Recently, a new partner has joined the fray: healthcare expertise. Major hedge funds are turning to doctors and scientists, seeking an edge in the volatile pharmaceut... |
| 04.12.2024 | Exclusive: Big hedge funds call on doctors, scientists for an edge on pharma | Exclusive: Big hedge funds call on doctors, scientists for an edge on pharma
By Nell MackenzieDecember 4, 20246:06 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Item 1 of 2 Pfizer's coronaviru... |
| 28.11.2024 | Syngene International Adopts Genedata Screener as Collaborative Solution for In Vitro Assay Analysis | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Genedata Screener used to ensure standardized assay data and data flow across pa... |
| 26.11.2024 | OmniScience's clinical trial genAI-powered control tower, Vivo, wins 1st place in the CNS Summit 2024 Innovation Showcase | Michael Bell, PhD, VP of Product at OmniScience, presents at the 2024 CNS Summit Innovation Showcase, highlighting how Vivo tackles the data challenges of clinical trials with genAI-driven insights
OmniScience was awarded top honors at the ... |
| 19.11.2024 | C Ray Therapeutics: A New Dawn in Radiopharmaceuticals | In the bustling landscape of biotechnology, C Ray Therapeutics has emerged as a beacon of innovation. This Chengdu-based startup recently completed a Series A+ funding round, raising over $100 million. The investment was co-led by Shenzhen ... |
| 19.11.2024 | 2024 Access to Medicine Index finds that pharma companies are missing opportunities to reach more patients in low- and middle-income countries | AMSTERDAM, Nov. 19, 2024 /PRNewswire/ -- The 2024 Access to Medicine Index finds that pharmaceutical companies are not fully leveraging their potential to expand access in underserved regions. While the Foundation's new analysis shows impro... |
| 19.11.2024 | TAHO Pharmaceuticals Initiates U.S. Phase III Clinical Trial of TAH3311 Antithrombotic Oral Dissolving Film, Dosing First Subjects | TAIPEI, Nov. 19, 2024 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. announced the dosing of the first subjects in its U.S. Phase III clinical trial for its lead product, TAH3311, an innovative antithrombotic oral dissolving film (ODF). In July ... |
| 18.11.2024 | C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital | CHENGDU, China, Nov. 18, 2024 /PRNewswire/ -- In November 2024, C Ray Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as "C Ray"), an innovative enterprise in the field of radiopharmaceuticals, announced the completion o... |
| 17.11.2024 | Chinese radiopharma firm C Ray raises over $100m Series A+ | Chinese radiopharmaceutical startup C Ray Therapeutics announced on Saturday that it has raised over $100 million in a Series A+ funding round to strengthen its technology platform and expedite the clinical development of pipeline drugs.
Ch... |
| 13.11.2024 | China's BeiGene Blows Past 2023 Earnings in Just Nine Months, Propelled by Cancer Drugs | (Yicai) Nov. 13 -- Chinese oncology firm BeiGene significantly boosted its revenue in the first three quarters of this year, surpassing its total revenue from last year, while also narrowing its losses, thanks to two successful cancer treat... |
| 08.11.2024 | Nongfu Spring's Zhong Retains Crown as China’s Richest Man on Forbes List | (Yicai) Nov. 8 -- Zhong Shanshan, founder of beverage giant Nongfu Spring, is the wealthiest person in China for the fourth straight year with a fortune of USD50.8 billion, despite his fortune shrinking USD9.3 billion due to fierce competit... |
| 28.10.2024 | Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New Funding | In the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn... |
| 25.10.2024 | Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell Medicines | Be Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo... |
| 23.10.2024 | Be Biopharma Raises $82M in Financing | Be Biopharma, a Cambridge, MA-based company which specializes in the discovery and development of engineered B Cell Medicines (BCMs), raised $82M in funding.
Backers included ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta... |
| 22.10.2024 | Terray Therapeutics: $120 Million (Series B) Secured To Improve Human Health | Terray Therapeutics, a biotechnology company focused on improving human health by transforming the speed, cost, and success rate of small molecule drug development using computation integrated with novel data at scale, announced Series B fu... |
| 22.10.2024 | HealthEx Raises $14M in Funding | HealthEx’s co-founders: CEO Priyanka Agarwal and CTO Anand Raghavan
HealthEx, a San Francisco, CA-based provider of a global consumer preference and consent platform for healthcare to unlock data access, raised $14M in Seed and Series A fun... |
| 20.10.2024 | Monument Therapeutics: Precision Neuroscience Company Raises £1 Million | Monument Therapeutics, a precision neuroscience company, announced a further £1 million equity investment by the Forster Foundation, a charitable incorporated organization. This new funding builds on equity and non-dilutive funding announce... |
| 19.10.2024 | MEDiC Life Sciences: Pioneering Cancer Solutions with $5 Million Boost | In the heart of Silicon Valley, a new force is emerging in the battle against cancer. MEDiC Life Sciences, a functional genomics startup, has secured a strategic investment of $5 million from LG and Hanmi Pharmaceutical. This funding marks ... |
| 18.10.2024 | MEDiC Life Sciences: Functional Genomics Company Raises $5 Million | MEDiC Life Sciences, a leading functional genomics startup in Silicon Valley, announced a $5 million strategic investment from LG and Hanmi Pharmaceutical. This funding comes ahead of MEDiC’s planned Series-A round later this year. Previous... |
| 17.10.2024 | Terray Therapeutics Closes $120M Series B Funding Round | Terray Therapeutics, a Los Angeles, CA-based biotechnology company improving human health by enhancing small molecule drug development, raised $120M in Series B funding.
The round was led by Bedford Ridge Capital and existing investor NVent... |
| 15.10.2024 | MEDiC Life Sciences Raises $5M in Strategic Funding | MEDiC Life Sciences, a Mountain View, CA-based functional genomics startup, raised $5M in strategic funding.
The round was led by LG and Hanmi Pharmaceutical.
The company intends to use the funds to accelerate the adoption of its cancer bio... |
| 13.10.2024 | World Thrombosis Day raises global awareness of blood clot dangers through actionable initiatives | Help shape the future of women's health by taking the survey and supporting this global campaign in its eleventh year to improve care for at-risk patients.
CHAPEL HILL, N.C., Oct. 13, 2024 /PRNewswire/ -- Today is World Thrombosis Day, a gl... |
| 08.10.2024 | RWD to the Rescue: Solving R&D Challenges for Pharma Companies, Upcoming Webinar Hosted by Xtalks | www.trinetx.com
In this free webinar, learn about using real-world data (RWD) to power the design of asset strategies and clinical trials. Attendees will gain insights into leveraging RWD to gain insights into cohorts, endpoints, feasibilit... |
| 04.10.2024 | Jeff Zevely to emcee the 2024 San Diego Miles for Melanoma 5K | Jeff Zevely
The Melanoma Research Foundation (MRF) is thrilled to announce that Jeff Zevely will be returning to emcee the annual Miles for Melanoma San Diego 5K event on Sunday, October 20, 2024 at De Anza Cove Park. Jeff will welcome gues... |
| 02.10.2024 | Owkin Partners with AstraZeneca for Advanced AI gBRCA Pre-Screening | Share
Tweet
Share
Share
Email
Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer.
Takeaway Points Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast canc... |
| 01.10.2024 | Aktis Oncology: $175 Million (Series B) Secured To Develop Targeted Alpha Radiopharmaceuticals For Treating Tumors | Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced the successful closing of an oversubscribed and u... |
| 30.09.2024 | Aktis Oncology Raises $175M in Series B Funding | Aktis Oncology, a Boston, MA-based clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, closed a $175m Series B financing.
The rou... |
| 28.09.2024 | Market Momentum: Dow Hits New Heights Amid Easing Inflation | The stock market is a living organism, constantly shifting and adapting. On September 27, 2024, the Dow Jones Industrial Average surged to a record high, propelled by a favorable inflation report. This news was like a gust of wind beneath t... |
| 27.09.2024 | Dow advances to record high after inflation report; small caps outperform | U.S. MarketsDow advances to record high after inflation report; small caps outperform
By Johann M Cherian and Purvi AgarwalSeptember 27, 20244:20 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
... |
| 25.09.2024 | Ученые обнаружили, что заразные формы рака вызваны изменением окружающей среды | У медузоподобных существ, называемых гидрами, при избыточном питании могут развиваться опухоли, которые, в свою очередь, могут передаваться их потомству. Новое исследование, посвященное этому явлению не только раскрыло подробности процесса ... |
| 19.09.2024 | Радиофармацевтические препараты назвали прорывом в борьбе с раком | Производители лекарств делают ставку на то, что доставка радиации непосредственно к опухолям станет следующим большим прорывом в борьбе с раком. Bristol Myers Squibb, AstraZeneca, Eli Lilly и другие фармацевтические компании потратили около... |
| 19.09.2024 | Transcenta Updates Encouraging Efficacy Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024 | Updated results with longer follow-up reveal confirmed ORR of 68% and median PFS of 14.2 months in patients with CLDN18.2 high or medium expression, known PD-L1 CPS (n=66).
PRINCETON, N.J. and SUZHOU, China, Sept. 19, 2024 /PRNewswire/ -- T... |
| 16.09.2024 | Circle Pharma Expands Leadership Team to Drive the Development of Its Pipeline of Oral Macrocycle Therapies | SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–September 16, 2024–
Circle Pharma, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, today announced ... |
| 15.09.2024 | Dialogue with CGT Leaders! You Are Invited to Join the "2024 GenScript Biotech Global Forum•London" to Discuss the Future Together | PISCATAWAY, N.J., Sept. 15, 2024 /PRNewswire/ -- The year 2024 marks a milestone year for continuous advancements in Cell and Gene Therapy (CGT). The global launch of Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, has ushered in a ... |
| 09.09.2024 | Стартап в сфере клеточной терапии ArsenalBio привлек $325 млн | В раунде финансирования Arsenal Biosciences приняли участие новые инвесторы ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures (венчурное подразделение NVIDIA), Luma Group, фонды, консультируемые T. Rowe Price... |
| 05.09.2024 | Novartis Expands Radioligand Therapy Manufacturing in the U.S. | In a bold move to combat cancer, Novartis is laying the groundwork for two new radioligand therapy (RLT) manufacturing facilities in the United States. This expansion is not just a step; it’s a leap into the future of cancer treatment. With... |
| 04.09.2024 | ArsenalBio: $325 Million (Series C) To Enhance Programmable Cell Therapy Programs | Arsenal Biosciences, a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, announced today the closing of an oversubscribed $325 million Series C financing round.
This fund... |
| 04.09.2024 | Ian Michael Crumm to emcee the 2024 New York Miles for Melanoma 5K | Ian Michael Crumm, 2024 New York Miles for Melanoma 5K event emcee
The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patien... |
| 04.09.2024 | Success! Cancer Survivor Julia Brookshire and Olympic Swimmer Janel Jorgensen McArdle Successfully Swim "World's Oldest" Hellespont and Dardanelles Open Water Swim | Julia Brookshire and Janel Jorgensen McArdle at the historic Hellespont and Dardanelles swim on August 30th, celebrating Brookshire’s CLL remission and raising funds for Swim Across America.
Swimmer Friends and Colleagues Completed Swim Aug... |
| 04.09.2024 | ArsenalBio Raises $325M in Series C Funding | ArsenalBio, a San Francisco, CA-based clinical stage programmable cell therapy company, raised $325M in Series C funding.
The round was led by ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures, Luma Group, fu... |
| 03.09.2024 | SKIES ACROSS NORTH AMERICA TO LIGHT UP THIS FALL IN SUPPORT OF BLOOD CANCER PATIENTS | The Leukemia & Lymphoma Society kicks off philanthropic campaign Light The Night; communities nationwide encouraged to learn why awareness and support is critical
RYE BROOK, N.Y., Sept. 3, 2024 /PRNewswire/ -- The Leukemia & Lymphom... |
| 03.09.2024 | ProofPilot Bolsters Advisory Board with Appointment of Michelle Everill | NEW YORK, Sept. 3, 2024 /PRNewswire/ -- ProofPilot, the leading Clinical Experience Platform (CXP) that centralizes and simplifies communication for sponsors, patients, and sites across the clinical trial experience, welcomes the addition o... |
| 03.09.2024 | Pharmaceutical Market: Trends, Segmentation, and Growth Opportunities | Share
Tweet
Share
Share
Email
In recent years, the pharmaceutical market has witnessed remarkable growth and transformation, driven by technological advancements, evolving consumer needs, and the global push for better healthcare solutions.... |
